Multidisciplinary management of acromegaly: a consensus

A Giustina, G Barkhoudarian, A Beckers… - Reviews in Endocrine …, 2020 - Springer
Abstract The 13th Acromegaly Consensus Conference was held in November 2019 in Fort
Lauderdale, Florida, and comprised acromegaly experts including endocrinologists and …

[HTML][HTML] A Pituitary Society update to acromegaly management guidelines

M Fleseriu, BMK Biller, PU Freda, MR Gadelha… - Pituitary, 2021 - Springer
Guidelines and consensus statements ensure that physicians managing acromegaly
patients have access to current information on evidence-based treatments to optimize …

[HTML][HTML] COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology

M Puig-Domingo, M Marazuela, BO Yildiz, A Giustina - Endocrine, 2021 - Springer
Background COVID-19 has completely changed our daily clinical practice as well as our
social relations. Many organs and biological systems are involved in SARS-Cov-2 infection …

[HTML][HTML] COVID-19 and the pituitary

S Frara, A Allora, L Castellino, L di Filippo, P Loli… - Pituitary, 2021 - Springer
Background Despite COVID-19 being identified as severe respiratory viral infection,
progressively many relevant endocrine manifestations have been reported greatly …

[HTML][HTML] Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective

M Fleseriu, M Buchfelder, JS Cetas, PK Fazeli… - Pituitary, 2020 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral strain that has
caused the coronavirus disease 2019 (COVID-19) pandemic, has presented healthcare …

Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide

SL Samson, LB Nachtigall, M Fleseriu… - The Journal of …, 2020 - academic.oup.com
Abstract Purpose The phase 3 CHIASMA OPTIMAL trial (NCT03252353) evaluated efficacy
and safety of oral octreotide capsules (OOCs) in patients with acromegaly who previously …

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY

M Fleseriu, D Führer-Sakel… - European journal of …, 2021 - academic.oup.com
Objective To report the final long-term safety and efficacy analyses of patients with
acromegaly treated with pegvisomant from the ACROSTUDY. Design Global (15 countries) …

High prevalence of vertebral fractures associated with preoperative GH levels in patients with recent diagnosis of acromegaly

S Frara, M Melin Uygur, L Di Filippo… - The Journal of …, 2022 - academic.oup.com
Context Osteopathy and morphometric vertebral fractures (VFs) are emerging complications
in acromegaly. However, the prediction of VFs in this clinical setting is still a matter of …

Global epidemiology of acromegaly: a systematic review and meta-analysis

S Crisafulli, N Luxi, J Sultana, A Fontana… - European journal of …, 2021 - academic.oup.com
Objective To date, no systematic reviews and meta-analysis on the global epidemiology of
acromegaly are available in the literature. The aims of this study are to provide a systematic …

Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review

N Agrawal, AG Ioachimescu - Pituitary, 2020 - Springer
Purpose Biochemical control is the main determinant of survival, clinical manifestations and
comorbidities in acromegaly. Transsphenoidal selective adenomectomy (TSA) is the initial …